Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-03-29
2005-03-29
Eyler, Yvonne (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S236100, C424S247100, C424S190100, C514S002600
Reexamination Certificate
active
06872397
ABSTRACT:
A method of treating a patient suffering from a disease, disorder or condition includes the administration to the patient of a therapeutically effective amount of botulinum toxin of a selected serotype until the patient experiences loss of clinical response to the administered botulinum toxin and thereafter administering to the patient a therapeutically effective amount of another botulinum toxin of a different serotype.
REFERENCES:
patent: 5183462 (1993-02-01), Borodic
patent: 5298019 (1994-03-01), Borodic
patent: 5401243 (1995-03-01), Borodic
patent: 5696077 (1997-12-01), Johnson et al.
patent: WO 940081 (1994-01-01), None
patent: WO 9400481 (1994-01-01), None
patent: WO 9428922 (1994-12-01), None
patent: WO 9517904 (1995-07-01), None
Jankovic et al., 1991, New England J. of medicine, vol. 324, No. 17, pp. 1186-1194.*
Ludlow et al., 1992, New England J. of medicine, vol. 326, No. 5, pp. 349-350.*
Simpson, L., 1981., Pharmacol. Reviews, vol. 33, No. 3, pp. 155-188.*
The Merck Manual of diagnosis and therapy, 1987. Merck Sharp and Dohme Researck Laboratories, NJ. pp. 1449-1551, 1420-1421.*
Athena files US and Canadian Investigational New Drugs(INDs);ScripJun. 5, 1992; No. 1724, p29.
Athena Makers a Wise Move; Medical Advertising News, Nov. 1992, p4.
Athena Outlines Business Strategy; Marketletter; Oct. 5, 1992, p N/A.
Blasl, Juan et al.;Botulinum Neurotoxin A Selectively Cleaves the Synaptic Protein SNAP—25; Nature; vol. 365, Sep. 9, 1993, pp160-163.
Brin, Mitchell;Interventional Neurology; Treatment of Neurological Conditions With Local Infection of Botulinum Toxin; Arch. De Neurobiol.; 54, Supl. 3, 1991 pp 7-23.
Dasgupta, Bibhuti;The Structure of Botulinum Neurotoxin; Botulinum Neurotoxin and Tetanus Toxin; Edited by Simpson, Lance; pp 53-67, 1989.
Gjerstad, Leif et al.;Treatment of Focal Dystonias With Botulinum Toxin; Translation Attached;Tidsskr Nor Laegeforen nr; 21, 1991; 111; pp2637-2639.
Jankovic, Joseph et al.;Therapeutic User ofBotulinum Toxin; The New England Journal of Medicine; Apr. 25, 1991, pp 1186-1991.
Moyer, Elizabeth et al.;Botulinum Toxin Type B: Experimental and Clinical Experience; Therapy With botulinum Toxin; Edited by Jankovic, Joseph et al.; pp 71-85, 1994.
Moyer, E. D. et al.;Effects of Intramuscular Injection of Botulinum Toxin Type B in Nonhuman Primates: Botulinum and Tetanus Neurotoxins; Edited by Dasgupta, B. R., pp665-666, 1992.
National Institutes of Health Consensus Development Conference Statement:Clinical Use of Botulinum Toxin: http://text.nlm.nih.gov
ih/cdc/www/83txt.html ; 18 pp. 1-18, 1990.
Poewe, W. et al.:Experience with Botulinum Toxin in Cervical Dystonia; Therapy with Botulinum Toxin; Edited by Jankovic, Joseph, pp 267-278, 1994.
Schantz, Edward et al.;Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine; American Society for Microbiology; vol. 56, 1992, pp 80-95.
Scott, Alan B. et al.:Systemic Toxicity of Botulinum Toxin by Intramuscular Injection in the Monkey; Movement Disorders; vol. 3, No. 4, 1988, pp 333-335.
Simpson, Lance L.;Clinically Relevant Aspects of the Mechanism of Action of Botulinum Neurotoxin; Journal of Voice, vol. 6, No. 4, 1992, pp 358-364.
Simpson, Lance L.;The Origin Structure, and Pharmacological Activity of Botulinum Toxin; Pharmacological Reviews, vol. 33, No. 3, pp155-188, 1981.
Tsui, J.K. et al.:A Pilot Study on the Use of Botulinum Toxin in Spasmodic Torticollis; The Canadian Journal of Neurological Sciences, vol. 12, No. 4, Nov. 1985, pp 314-316.
Tsui, J.K. et al.:Botulinum Toxin Type B in the Treatment of Cervical Dystonia: A Pilot Study; Neurology, Nov. 1995, 45(11). pp 2109-2110.
Tsui, J.K. et al.:Local Treatment of Spasmodic Torticollis with Botulinum Toxin: Le Journal Canadien Des Sciences Neurologiques, vol. 14, No. 3 (Supplement), Aug. 1987. pp 533-535.
U.S. Food and Drug Administration;List of Orphan Designations and Approvals: http://www.fda.gov/orphan/designat/list.htm, 1984-1999, 6 pp out of 257.
Borodic, G.E., et al.,Botulinum B Toxin as an alternative to Botulinum A Toxin: A Histologic Study, Ophthalmic Plastic and Reconstructive Surgery, vol. 9, No. 3, pp 182-190, 1993.
Schantz, E.J., et al.,Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews, Mar. 1992, pp. 80-99, vol. 56, No. 1.
Sellin, L.C., et al.,Different effects of types A and B botulinum toxin on transmitter release at the rat neuromuscular junction, Acta Physiolo Scand 1983, 119:127-133.
Aoki K. Roger
Carlson Steven R.
Grayston Michael W.
Leon Judith M.
Allergan Inc.
Chernyshev Olga N.
Donovan Stephen
Eyler Yvonne
LandOfFree
Method for treating neuromuscular disorders and conditions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating neuromuscular disorders and conditions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating neuromuscular disorders and conditions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3419764